BRIEF-Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
Reuters2026/08/18 12:56Akari Therapeutics PLC AKTX.O:
AKARI THERAPEUTICS - AKTX-101 DEMONSTRATES ROBUST ANTI-TUMOR ACTIVITY IN UROTHELIAL CANCER PRECLINICAL MODELS
AKARI THERAPEUTICS - PH1 PAYLOAD SHOWS POTENTIAL TO OVERCOME PAYLOAD-SPECIFIC RESISTANCE
AKARI THERAPEUTICS - CONTINUES TO ADVANCE IND-ENABLING ACTIVITIES FOR AKTX-101 WITH GOAL OF INITIATING PHASE 1 CLINICAL TRIAL IN MID-2027
AKARI THERAPEUTICS - AKTX-101 ACHIEVES STATISTICALLY SIGNIFICANT TUMOR GROWTH INHIBITION IN UROTHELIAL CARCINOMA MODEL
AKARI THERAPEUTICS - DEVELOPING AKTX-102 ADC TARGETING CEACAM5 IN MULTIPLE SOLID TUMORS
Source text: ID:nGNX7FHXTR
Further company coverage: AKTX.O
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Web3: XAUT deposits on Aave increase to $76.7 million
Anthropic's pre-IPO credit line may exceed 10 billion dollars
Johnson & Johnson On Pace for Record High Close -- Data Talk
